China Liquid Biopsy Market Size & Outlook, 2023-2030
China liquid biopsy market, 2018-2030 (US$M)
Related Markets
China liquid biopsy market highlights
- The China liquid biopsy market generated a revenue of USD 756.6 million in 2023 and is expected to reach USD 1,765.6 million by 2030.
- The China market is expected to grow at a CAGR of 12.9% from 2024 to 2030.
- In terms of segment, blood sample was the largest revenue generating type in 2023.
- Blood Sample is the most lucrative type segment registering the fastest growth during the forecast period.
Liquid biopsy market data book summary
| Market revenue in 2023 | USD 756.6 million |
| Market revenue in 2030 | USD 1,765.6 million |
| Growth rate | 12.9% (CAGR from 2023 to 2030) |
| Largest segment | Blood sample |
| Fastest growing segment | Blood Sample |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Sample |
| Key market players worldwide | ANGLE PLC, Guardant Health Inc, Myriad Genetics Inc, Biocept Inc, Lucence Health, Roche, Qiagen NV, Illumina Inc, Thermo Fisher Scientific Inc, Epigenomics AG, Oncimmune, Freenome |
Other key industry trends
- In terms of revenue, China accounted for 7.1% of the global liquid biopsy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China liquid biopsy market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 29.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liquid Biopsy Market Scope
Liquid Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China liquid biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liquid biopsy market will help companies and investors design strategic landscapes.
Blood sample was the largest segment with a revenue share of 73.28% in 2023. Horizon Databook has segmented the China liquid biopsy market based on blood sample covering the revenue growth of each sub-segment from 2018 to 2030.
Lung cancer is the leading cause of mortality in China. On the other hand, prostate cancer is the fastest growing cancer type in the country and the second leading cause of cancer mortality in the Western world.
According to the Chinese Medical Journal, the country accounted for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide in 2020.
The government has undertaken various initiatives, such as free cervical cancer screening campaigns for women of all ages and collaborations with nonprofit organizations to improve the accessibility of the tests.
Reasons to subscribe to China liquid biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China liquid biopsy market databook
-
Our clientele includes a mix of liquid biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China liquid biopsy market , including forecasts for subscribers. This country databook contains high-level insights into China liquid biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China liquid biopsy market size, by type, 2018-2030 (US$M)
China Liquid Biopsy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
